Home › Amyloidosis › NCT07358078

DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting

DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With Transthyretin-Mediated Amyloidosis With Cardiomyopathy in a Real-World Setting

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Has a diagnosis of ATTR-CM
* Is initiating treatment with vutrisiran or another approved ATTR-CM therapy

Exclusion Criteria:

* Is enrolled in an interventional clinical trial

About the study

The purpose of this study is to:

* Describe the clinical characteristics of adult patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) treated with vutrisiran in routine clinical care * Describe treatment patterns of adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Assess health-related quality of life (HRQOL) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Assess healthcare resource use (HCRU) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Compare the long-term effectiveness of vutrisiran versus other approved ATTR-CM treatments in routine clinical care

Sponsor: Alnylam Pharmaceuticals · Participants: 2,000 · Started: Jan 9, 2026

Contact the study team

• Clinical Trial Information Line · Phone: 1-877-ALNYLAM
• Clinical Trial Information Line · Phone: 1-877-256-9526

Official record on ClinicalTrials.gov — NCT07358078

Locations in the U.S.

Conditions

• Amyloidosis
• Cardiomyopathy

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.